Apellis Pharmaceuticals Faces Selloff Due to EU Opinion, Investors Optimistic for Rebound as RSI Oversold

Apellis Pharmaceuticals Inc. ($APLS) has experienced a significant selloff in its stock, dropping from the 40s due to a negative opinion from the EU, which was not considered in the overall valuation. Despite this, there is optimism among investors that the stock will rebound. Some investors are holding long positions and call options, expecting the stock to trend back into the 40s. Additionally, the company's revenue figures have been promising, and the sentiment from recent sessions has been positive. The stock's RSI indicates it is oversold, suggesting a potential bounce in the coming weeks. The stock moved from red to green and likely bottomed yesterday.